Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.

Liu, Wei Zhen; Du, Yu Qiang; Shen, Qian; Tao, Kai Xiong; Zhang, Peng

Liu, Wei Zhen; Du, Yu Qiang; Shen, Qian; Tao, Kai Xiong; Zhang, Peng.

Afiliación

Liu WZ; Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Du YQ; Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Shen Q; Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Tao KX; Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Zhang P; Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.

J Dig Dis ; 2023 Sep 14.

Article en En | MEDLINE | ID: mdl-37706279

Palabras clave

drug resistance; gastrointestinal stromal tumors; imatinib mesylate; ripretinib; tyrosine protein kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Dig Dis Año: 2023 Tipo del documento: Article País de afiliación: China